

# Stock Sentiment Analysis Report

Illumina (ILMN)

Analysis Period: 2026-03-03 to 2026-04-02 (30 days)

Generated: 2026-04-02 09:17:33

# Executive Summary

## Executive Summary: Illumina (ILMN) Sentiment Analysis

During the period of March 3 to April 2, 2026, sentiment analysis for Illumina (ILMN) indicates a largely neutral media landscape, characterized by a near-even distribution of positive and negative mentions. Out of 194 analyzed items, 37.6% were classified as neutral, 31.4% as positive, and 30.9% as negative. Key positive drivers stemmed from advancements in genomic research, including studies on immune dynamics in viral infections and microbial growth rates, alongside broader market opportunities in Artificial Intelligence in Oncology. Conversely, negative sentiment was primarily associated with challenges and corrections within cancer research and diagnostics, reflecting the inherent complexities of the scientific domain.

Significant positive events included research highlighting immune responses to EBV infection (Plos.org, score 0.84) and the rapid growth of the AI in Oncology market projected for 2026-2030 (GlobeNewswire, score 0.80), underscoring potential for genomics integration. On the negative side, a "Publisher Correction" related to liquid biopsy and tumor tissue genomic profiling in appendiceal cancer (Pubmed, score -0.87) represented the most impactful negative item. Other negative mentions focused on complexities in biobanking and genomic assessments for various cancers, such as integrating ctDNA metrics in breast cancer (ESMO open, score -0.80). These reflect ongoing scientific challenges rather than direct corporate setbacks for Illumina.


## Sentiment Breakdown

Category	Count	Percentage
Positive	61	31.4%
Negative	60	30.9%
Neutral	73	37.6%
<b>Total</b>	<b>194</b>	<b>100.0%</b>

**Overall Sentiment: MIXED**

## Sentiment Trend Over Time

### Illumina (ILMN) - Sentiment Trend (30 Days)



## Key Findings

Finding
✓ EBV infection outcomes determined by monocyte and TREG-driven immune dynamics in an ex vivo pbmc model
✓ Microbial growth rates captured using Raman-SIP reveal a highly active subsurface biosphere fueled by serpentinization
✓ I'm a wellness writer — 40 of my favorite products just hit Amazon's Spring Sale
✗ Publisher Correction: Integrated Liquid Biopsy and Tumor Tissue Genomic Profiling of Appendiceal Cancer: cfDNA Burden, Mutation Landscapes, and Clinical Outcomes.
✗ Biobanking of gynecologic cancer biospecimens: Development, quality control, and translational applications
✗ New   phs004508.v1.p1   Dendritic Cell Redundancy Enables Priming of Anti-Tumor CD4 T Cells in Pancreatic Cancer

## Top Positive Events

Title	Source	Date	Score
EBV infection outcomes determined by monocyte and ...	news	2026-03-20	0.840

Microbial growth rates captured using Raman-SIP re...	news	2026-03-18	0.812
I'm a wellness writer — 40 of my favorite products...	news	2026-03-25	0.805
Artificial Intelligence in Oncology: Assessment of...	news	2026-03-30	0.799
Plagl1 regulates the retinal progenitor cell to Mü...	news	2026-03-18	0.784

## Top Negative Events

Title	Source	Date	Score
Publisher Correction: Integrated Liquid Biopsy and...	pubmed	2026 Apr 1	-0.872
Biobanking of gynecologic cancer biospecimens: Dev...	news	2026-03-31	-0.869
New   phs004508.v1.p1   Dendritic Cell Redundancy ...	news	2026-03-27	-0.869
Assessment of references for the quantitative anal...	news	2026-03-23	-0.869
Integrating baseline ctDNA-derived tumor metrics e...	pubmed	2026 Mar 3	-0.796